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Prostate cancer (PCa) is the second most common histologically 
diagnosed malignancy in South African men, with an estimated 
annual incidence rate of 17.8/100 000.1 The age-standardised 
incidence rate (ASIR) of PCa in South African men in the 55 - 
59-year age range is 56/100 000; this figure rises to 455/100 000 in 
men older than 75 years.1 In North America, incidences of PCa are 
the highest in black men, intermediate in white men and the lowest 
in Asian men.2 In South Africa, the highest incidence is reported in 
white men (Northern European ancestry) and the lowest in black 
and Asian men, with an intermediate incidence reported for coloured 
(mixed ancestry) men.1 However, substantial under-diagnosis and 
under-reporting may be the reason for the low incidence in South 
African black men.3
It has been suggested that ethnic differences in incidence and 
mortality of PCa are related to genetic variations in genes that 
regulate androgen metabolism. Studies addressing this hypothesis 
have demonstrated that genes that regulate androgen metabolism are 
associated with PCa susceptibility. Findings include genes that encode 
proteins belonging to the cytochrome P450 (CYP) family (a group of 
enzymes that are involved in the metabolism of xenobiotics, steroids, 
vitamins and sex hormones).4 The CYP3A subfamily is a group of 
enzymes that are key deactivators of testosterone. The CYP3A locus 
consists of four genes, CYP3A5, CYP3A7, CYP3A4 and CYP3A43, 
each gene containing 13 exons and located on chromosome 7q21-
22.1. We did not screen CYP3A7 because it is predominantly 
expressed in fetal stages of development4 and we therefore considered 
it unlikely to play a role in the pathogenesis of PCa.
The CYP3A5 enzyme catalyses the 6β-hydroxylation of testosterone, 
producing a less biologically active form of testosterone that is more 
readily eliminated.4 The single nucleotide polymorphism (SNP) 
rs776746 (6986A>G; in some publications the A allele = CYP3A5*1 
and G allele = CYP3A5*3) in intron 3 creates a cryptic splice site 
resulting in a messenger ribonucleic acid (mRNA) that is more 
unstable and more rapidly degraded than the mRNA formed by 
the wild-type A allele.4 In Finnish men, the rs776746 A allele was 
significantly associated with PCa bone metastases.5 
The CYP3A4 enzyme is involved in the oxidation of testosterone 
to 2β-, 6β- or 15β-hydroxytestosterone. For the SNP rs2740574 
(-392A>G; the A allele = CYP3A4*1A and G allele = CYP3A4*1B) in 
the 5´ regulatory region of the gene, the G allele was initially shown to 
be associated with PCa in white and black American men,6 which was 
replicated in subsequent investigations. In black American men, no 
association was found between the rs2740574 A or G alleles, or other 
SNP alleles in CYP3A4, and the probability of developing PCa.7 
CYP3A43 is expressed predominantly in the prostate and less 
significantly in the testis, kidney and pancreas.8 The CYP3A43 
enzyme is inactive, but splicing of CYP3A43 exon 1 to CYP3A4 
and CYP3A5 exons produces hybrid mRNA products, of which 
the longest CYP3A43/CYP3A4 chimeric isoform can hydroxylate 
testosterone.8 An association was demonstrated between the G 
allele of rs680055 (60084G>C [Pro340Ala]) and the probability of 
developing PCa in white American men with a positive family history 
of the disease,6 while an association was observed between the G 
allele and probability of PCa in black American men, after adjusting 
for age and pack-years of cigarette smoking.9 A significant association 
was demonstrated between the rs680055 G allele and probability of 
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developing PCa in white American men with a history of benign 
prostatic hyperplasia (BPH).10 We did not screen rs680055 and chose 
to screen the SNP rs501275 (75726T>C) in CYP3A43 because we 
considered it to be more polymorphic in our screening population of 
coloured and white men. 
Little PCa genetic research has been undertaken in South Africa. We 
have reported associations between SNP alleles in a gene involved in 
mediating inflammatory responses and the probability of developing 
PCa in South African men.11 In the present study, we screened genetic 
variants in the androgen metabolism genes CYP3A5, CYP3A4 and 
CYP3A43 to determine whether these play a role in the development 
of PCa and report findings of our case-control genetic association 
study of self-reported South African coloured and white men. 
Methods
Study population
Unrelated men from the South African coloured and white ethnic 
groups were enrolled in the case-control study to determine genetic 
factors associated with the probability of developing PCa. The study 
comprised 160 coloured individuals (mean age 69 (range 47 - 88) 
years) and 121 white individuals (mean age 71 (range 48 - 90) years) 
with histologically confirmed PCa. All were from the Western Cape 
province of South Africa and had undergone radical prostatectomy, 
transurethral resection of the prostate or prostatic biopsy in the 
Department of Urology at Tygerberg Hospital. Control individuals 
were selected from subjects admitted to the same hospital during the 
same period and comprised 146 coloured men (mean age 65 (range 
52 - 91) years) and 141 white men (mean age 67 (range 52 - 88) years) 
from the same geographical region. 
Blood samples were collected from each subject. Clinical 
characteristics, including prostate-specific antigen (PSA), Gleason 
grade, tumour node metastasis (TNM) stage, age at diagnosis 
and family history, were obtained from medical records. Controls 
had PSA levels ≤2.5 ng/ml and normal findings on digital rectal 
examination (DRE). Subjects were informed and gave written consent 
to participate and allow their biological samples to be genetically 
analysed, according to the Helsinki Declaration. The study was 
approved by the Faculty of Health Sciences Human Research Ethics 
Committee, Stellenbosch University.
SNP genotyping
Genomic deoxyribonucleic acid (DNA) was extracted from whole 
blood using a QIAamp DNA kit (Qiagen, GmbH). The polymerase 
chain reaction restriction fragment length polymorphism (PCR-
RFLP) method used to determine the CYP3A4 rs274057412 and 
CYP3A5 rs77674613 genotypes has been reported previously. For 
PCR amplification of the CYP3A43 rs501275 polymorphism we 
used the primers F 5´-GTCAATGGCAATTTTCTGTT-3´ and 
R 5´-CTGTCTTCACAAACCAGATG-3´ in a 50 µl reaction mix 
containing 50 ng of genomic DNA, 120 ng of each of the forward (F) 
and reverse (R) primers, 200 µM of dATP, dCTP, dGTP and dTTP, 
1.5 mM MgCl2, 1 µl 10 × Taq DNA polymerase buffer, and 0.5 U 
Taq DNA polymerase. PCR conditions were as follows: 7 minutes 
at 94°C; 30 cycles of 30 seconds at 94°C, 30 seconds at 52°C, and 45 
seconds at 72°C; and finally 5 minutes at 72°C. The 210 base pair 
(bp) PCR amplification product was digested with the restriction 
enzyme RsaI (Promega, USA) in a volume of 10 µl for 2 hours at 
37°C. The restriction fragments were analysed in a 3% agarose gel 
stained with ethidium bromide. A fragment at 210 bp corresponds 
to a homozygous wild-type genotype (TT) and two fragments at 
119 bp and 91 bp correspond to the homozygous variant genotype 
(CC). Three fragments at 210 bp, 119 bp and 91 bp represent the 
heterozygous genotype (TC).
Statistical analysis
Genotype and allele counts and frequencies were calculated for 
each SNP. Haplotype frequencies were inferred for a haplotype 
consisting of allele combinations, one allele from each gene. Each 
polymorphism was tested in the control individuals to confirm 
that they were in Hardy-Weinberg equilibrium (HWE). Linkage 
disequilibrium (LD) (the concept of alleles inherited together at a 
frequency higher than by chance) between adjacent polymorphisms 
was assessed. We tested each SNP for an ethnic-genetic interaction 
for probability of developing PCa. For each SNP in each ethnic 
group, we tested additive allelic association with PCa, adjusted for 
age. This provided p-values and estimated allelic odds ratios (ORs), 
which are the number with which the odds are multiplied, for each 
additional copy of a specific allele. We adjusted for ethnicity and 
age in the combined group, and because the South African coloured 
population is mixed, we corrected for their population stratification 
by multiplying the obtained p-values by an inflation factor (λ) of 
3.06, which we had determined previously in a study on the same 
group.11 We used the same inflation factor to correct the p-values for 
the combined ethnic groups, which is very conservative because it is 
only required for the coloured individuals in the combined group. 
PCa ORs (and 95% confidence intervals (CIs)) for specific haplotypes 
compared with the reference (highest frequency) haplotype were 
estimated, as previously described.11 We used logistic regression 
models to test the additive allelic association with PCa and estimate 
the ORs (with corresponding 95% CIs), while adjusting for age by 
including it as a covariate in the models. Logistic regression was used 
to test genotype-ethnicity interaction on the probability of developing 
PCa, and to test haplotype association with PCa. Analyses were done 
in R, a language and environment for statistical computing available 
from http://www.R-project.org. The R packages genetics, LDheatmap 
and haplo.stats were used. 
Results
Genotypes were compared within each of the two ethnic groups for 
rs776746, rs2740574 and rs501275. All three SNPs were in HWE 
among the controls in both populations (results not shown). For the 
purpose of this study, the rs776746 A allele was considered the variant 
allele because it occurred at a lower frequency in both populations, 
although biologically it produces the wild-type protein product. 
For the coloured group, after adjusting for age, a significant 
association with PCa was observed for the rs2740574 G allele (OR 
1.93; 95% CI 1.29 - 2.95; p=0.0014) (each G allele almost doubles 
the odds of PCa) and the rs501275 C allele (OR 1.52; 95% CI 1.01 
- 2.31; p=0.0429) (Table I). However, after correcting for population 
stratification, only the effect of the rs2740574 G allele remained 
significant (p=0.0043) (Table I). For the white group, after adjusting 
for age, a significant association with PCa was observed for the 
rs776746 A allele (OR 1.87; 95% CI 1.04 - 3.80; p=0.0358) and 
rs2740574 G allele (OR 5.11; 95% CI 2.50 - 11.44; p<0.0001). There 
was no significant interaction between ethnicity and genotype on 
case-control status. We could therefore combine the two ethnic 
groups, which showed significant associations with PCa with the 
variant alleles of all three SNPs, although only the association of the 
rs2740574 G allele and rs501275 C allele remained significant after 
correcting for the effect of population stratification in the coloured 
group (Table II). Across the case and control groups in both ethnic 
groups we observed statistically significant LD between the SNPs 
(results not shown).
In the white group, a highly significant difference in frequency of 
the most common haplotype, GAT, was observed between case and 
control individuals (p<0.0001) (Table III). The inferred frequency was 
88% in the control group versus 71% in the case group. In coloured 
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men, we observed the same trend, 44% in the control group and 40% 
in the case group, but it was not statistically significant (Table III). In 
the combined ethnic groups, haplotype GAT was also significantly 
less prevalent in the PCa case individuals (54%) than in the controls 
(67%) (Table III). In coloured men, haplotypes AGT, AGC and GCC 
were significantly more prevalent in the case group than in the 
control group (Table III). In white men, only haplotype GGT showed 
a highly significant difference, 11% in the case group and 1% in the 
control group (Table III). For the combined ethnic groups analysis, 
haplotypes GGT, AGT, AGC and GGC were significantly more 
prevalent in the case group than in the control group (Table III).
Discussion
Our findings support the involvement of CYP3A5, CYP3A4 and 
CYP3A43 alleles in the probability of developing PCa in South 
African men. We report a unique finding indicating increased 
PCa probability associated with the rs776746 A allele (CYP3A5*1). 
Additionally, we confirmed an association between the rs2740574 G 
allele (CYP3A4*1B) and PCa occurrence.6
We demonstrated that the rs776746 A allele was associated with 
developing PCa in South African white men, whereas in Finnish 
men the allele was not associated with development of PCa but 
was associated with bone metastases (disease progression).5 The 
Table II. Genotype and allele count and frequency distributions and age and ethnicity-adjusted additive allelic prostate cancer ORs 
with 95% CIs and p-values among CYP3A5, CYP3A4 and CYP3A43 SNPs in a combined group of coloured and white South African 
men
            Cases   Controls
            (N=281)  (N=287)
SNP  Genotype          N (%)   N (%)       OR (95% CI)                  p-value
CYP3A5  GG          140 (50)  180 (63)              1.00
rs776746  GA          101 (36)  73 (25)
  AA          40 (14)  34 (12)
  A allele          181 (32)  141 (25)      1.37 (1.04 - 1.82)  0.0262
            0.0802*
CYP3A4  AA          147 (52)  218 (76)              1.00
rs2740574  AG          117 (42)  66 (23)
  GG          17 (6)   3 (1)
  G allele          151 (27)  69 (13)      2.51 (1.76 - 3.61)  <0.0001
            <0.0001*
CYP3A43  TT          177 (63)  213 (74)              1.00
rs501275  TC          94 (33)  70 (24)
  CC          10 (4)   4 (2)
  C allele          114 (20)  78 (14)      1.60 (1.13 - 2.29)  0.0086
            0.0263*
*Corrected p-value for the effect of population stratification in coloured men obtained by multiplying age-adjusted value by an inflation factor λ = 3.06 (Fernandez et al., 200811).
Table I. Genotype and allele count and frequency distributions and age-adjusted additive allelic ORs with 95% CIs and p-values for prostate cancer 
among CYP3A5, CYP3A4 and CYP3A43 SNPs in South African coloured and white men
                    Coloured               White
           Cases  Controls     Cases         Controls
           (N=160) (N=146)     (N=121)         (N=141)
SNP Genotype          N (%) N (%)          OR (95% CI)        p-value N (%)         N (%)  OR (95% CI) p-value
CYP3A5       GG          46 (29) 55 (38)  1.00   94 (78)         125 (89) 1.00
rs776746       GA          77 (48) 59 (40)     24 (20)         14 (10)
       AA          37 (23) 32 (22)     3 (2)         2 (1) 
    A allele          151 (47) 123 (42)          1.26 (0.91 - 1.73)     0.1588  30 (12)          18 (6)  1.87 (1.04 - 3.80) 0.0358
              0.4859*
CYP3A4       AA          63 (39) 87 (60)  1.00   84 (69)         131 (93) 1.00
rs2740574       AG          82 (52) 56 (38)     35 (29)         10 (7)
       GG          15 (9) 3 (2)     2 (2)         0 
   G allele          112 (35) 62 (21)          1.93 (1.29 - 2.95)     0.0014  39 (16)          10 (4)  5.11 (2.50 - 11.44) <0.0001
              0.0043*
CYP3A43       TT          79 (49) 89 (61)  1.00   98 (81)         124 (88) 1.00
rs501275       TC          71 (45) 53 (36)     23 (19)         17 (12)
       CC          10 (6) 4 (3)     0         0
    C allele          91 (28) 61 (21)          1.52 (1.01 - 2.31)     0.0429  23 (10)          17 (6)  1.83 (0.92 - 3.74) 0.0869
              0.1312*
*Corrected p-value for the effect of population stratification in coloured men obtained by multiplying age-adjusted value by an inflation factor λ = 3.06 (Fernandez et al., 200811).
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sample size of our case individuals limited the analytical power to 
test for associations between the SNP alleles and disease extent. 
Individuals harbouring at least one copy of the A allele express large 
amounts of CYP3A5, whereas having a copy of the variant G allele 
causes alternative splicing and protein truncation resulting in an 
absence of CYP3A5.4 Men with the A allele would therefore have 
increased testosterone oxidation, which decreases the bio-availability 
of testosterone for conversion to 5α-dihydrotestosterone (5α-DHT), 
the principal androgenic hormone involved in regulating prostate cell 
growth (more testosterone oxidation = less 5α-DHT = less prostate 
cell growth). Our association with the A allele contradicts this 
hypothesis, although it might lend support to this variant being in LD 
with the causal variant in CYP3A5 or a nearby gene.
The CYP3A4 rs2740574 G allele has been associated with PCa 
aggressiveness.6 We did not stratify the case individuals by disease 
aggressiveness because of our small sample size. No substantial effect 
of the G allele variant on CYP3A4 expression has been identified.14 
However, it has been shown in white individuals that the CYP3A4 
rs2740574 polymorphism is in tight LD with the CYP3A5 rs776746 
polymorphism.4,6,15 Furthermore, it has been suggested that reported 
associations between the variant G allele and PCa could be due to 
the polymorphic CYP3A5 expression.15 We observed significant 
LD between rs776746 and rs2740574, lending support to possible 
synergistic interaction between their alleles in PCa development in 
South African men.
Associations have been reported with a specific allele of the 
CYP3A43 coding SNP rs680055 and PCa, only after stratifying for a 
positive family history of PCa,6 a history of cigarette smoking9 or a 
history of BPH.10 We observed a direct association with the CYP3A43 
rs501275 C allele and PCa probability only in our combined analysis. 
It is unclear why the C allele increased probability of the disease, 
given that CYP3A43 has been suggested to be a pseudogene,4 having 
a specific role of contributing exons to CYP3A5 and CYP3A4 
transcripts to produce hybrid mRNAs.8 Moreover, it is unclear how 
the rs501275 polymorphism in intron 4 of the gene could play a 
role in PCa causation as it is probably non-functional. Because the 
CYP3A locus exhibits significant LD, the association with CYP3A43 
might alternatively reflect the effect of another variant in the gene, or 
in CYP3A5 or CYP3A4. 
We report significant differences in haplotype frequency 
distributions by PCa case-control status, with and without stratifying 
by ethnicity. The higher frequency of haplotype GAT in the control 
individuals (Table III) might suggest that this haplotype is protective 
against developing PCa in white South African men. The CYP3A5-
CYP3A4-CYP3A43 haplotypes may contain additional information 
about disease probability prediction beyond single SNP analysis, 
suggesting that other variants in these genes or variants in other genes 
in the region may be involved in the development of PCa.
Limitations of our study include the small sample size, although it 
was sufficient to detect small to moderate associations. Additionally, 
the sample size limited our ability to test for associations with disease 
aggressiveness or disease extent. Cytochromes metabolise xenobiotics 
and an association with PCa and pack-years of cigarette smoking 
has been demonstrated.9 Information related to cigarette smoking 
and alcohol use was occasionally omitted in medical records, and 
our control individuals were not obliged to indicate cigarette and 
Table III. Inferred haplotype frequencies, prostate cancer ORs and joint p-values for tests of association with prostate cancer for each 
haplotype in South African coloured and white men 
      Haplotype frequency (%)
          rs776746            rs2740574             rs501275        Controls       Cases             OR (95% CI)  p-value
Coloured                G        A  T             44           40  1.00  0.0975
                A        A  C             7           4           0.59 (0.22 - 1.58) 0.1076
                A        A  T             22           16           0.74 (0.43 - 1.29) 0.0709
                G        A  C             5           5           1.30 (0.52 - 3.25) 0.9193
                G        G  T             7           3           0.48 (0.17 - 1.36) 0.2537
                A        G  T             5           12           2.98 (1.29 - 6.88) 0.0067
                A        G  C             8           15           2.54 (1.28 - 5.03) 0.0011
                G        G  C             1           5           3.51 (0.83 - 14.87) 0.0383
White                G        A  T             88           71  1.00  <0.0001
                A        A  C             1           2           3.12 (0.36 - 27.01) 0.2878
                A        A  T             3           7           2.04 (0.87 - 4.82) 0.1571
                G        A  C             4           4           1.32 (0.51 - 3.41) 0.9519
                G        G  T             1           11           12.32 (3.56 - 42.58) <0.0001
                A        G  T             1           2           2.39 (0.46 - 12.56) 0.2268
                A        G  C             1           2           2.37 (0.58 - 9.78) 0.2216
                G        G  C             0           1
Combined                G        A  T             67           54  1.00  0.0000
                A        A  C             4           3           0.84 (0.37 - 1.88) 0.4284
                A        A  T             12           12           1.06 (0.70 - 1.60) 0.6206
                G        A  C             4           4           1.38 (0.72 - 2.65) 0.9954
                G        G  T             4           6           2.43 (1.26 - 4.68) 0.0108
                A        G  T             4           8           2.61 (1.38 - 4.94) 0.0014
                A        G  C             5           10           2.79 (1.59 - 4.92) 0.0001
                G        G  C             1           3           4.45 (1.32 - 15.00) 0.0055
Coloured men global p-value = 0.0004; white men global p-value <0.0001; combined global p-value <0.0001.
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alcohol use; we were therefore unable to incorporate these data into 
our analyses. However, future studies with larger sample sizes and 
collection of all relevant covariates should address these limitations. 
Conclusions
We detected variants in genes at the CYP3A locus that are associated 
with PCa in South African men. Our previous findings support the 
role of genes involved in inflammation and the development of PCa 
in South African coloured men.11 This study supports the role of 
genetic variants in genes that regulate androgen metabolism in the 
development of PCa in South African men. It has been suggested that 
prostate tumours initiated under conditions of chronic inflammation 
are fed by exposure to androgens, resulting in clinically more severe 
tumours.10 Our study does not conclusively identify a PCa causative 
variant, although it strongly suggests that the causative variant may 
lie within or closely adjacent to the CYP3A locus. Further studies in 
larger sample sizes and in other South African population groups 
should confirm the associations in CYP3A5, CYP3A4 and CYP3A43, 
or identify associations in other genes in the region, which will 
allow stratified analyses by disease aggressiveness. This could lead to 
uncovering the genetic relationship between genotype and haplotype 
profiles associated with disease progression and prognosis.
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RESEARCH LECTURE
Should we be giving antiretroviral drugs to  
HIV-negative people?
The fourth prestigious Research Lecture hosted by the Faculty of Health Sciences Research Office, University of the Witwatersrand (Wits) 
will be held on 25 November 2010 in the Johannesburg Hospital Auditorium. 
New results show that an antiretroviral vaginal gel can partially prevent HIV infection transmitted by vaginal intercourse. Other research 
studies that use antiretroviral drugs (ARVs) to prevent HIV infection are currently in the pipeline, with the results expected soon. 
Should these results show that ARVs can be used to prevent HIV, we will be faced with a number of financial, ethical and programmatic 
dilemmas.
At a time when South Africa is struggling to afford ARVs for treatment, should the use of ARVs for prevention be considered? If the 
answer is yes, can the country afford to offer these medications to anyone at risk of HIV, or will we have to decide which groups should 
be targeted for this intervention? If we roll out these medications widely, will the emergence of drug resistance become a problem among 
those who become HIV positive and in the broader community, and what impact will this have on the treatment programme?
These issues will be debated by Professor Helen Rees, Executive Director of the Wits Institute for Sexual and Reproductive Health, HIV 
and Related Diseases, Professor in the Wits Department of Obstetrics and Gynaecology and Honorary Professor in the London School 
of Hygiene and Tropical Medicine, and Professor Lynn Morris, Head of the AIDS Unit, Division of Virology and Communicable Disease 
Surveillance, National Institute for Communicable Diseases and Research Professor in the Faculty of Health Sciences at Wits. 
